Baker Chad R Sells 6,075 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Baker Chad R trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 93,205 shares of the company’s stock after selling 6,075 shares during the period. Baker Chad R owned about 0.11% of CRISPR Therapeutics worth $3,669,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Northwestern Mutual Wealth Management Co. increased its holdings in CRISPR Therapeutics by 4.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after purchasing an additional 211 shares during the period. Boston Family Office LLC grew its position in shares of CRISPR Therapeutics by 2.2% during the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock worth $459,000 after buying an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC increased its stake in shares of CRISPR Therapeutics by 0.8% during the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after buying an additional 218 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after acquiring an additional 231 shares in the last quarter. Finally, Sunbelt Securities Inc. lifted its stake in CRISPR Therapeutics by 11.3% in the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock worth $139,000 after acquiring an additional 300 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CRSP. Chardan Capital restated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $40.53 on Friday. The business has a fifty day moving average of $45.01 and a 200 day moving average of $48.16. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -14.32 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the business posted ($1.41) earnings per share. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.